- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
TiGenix’s Crohn’s disease drug granted Swiss orphan drug designation
18 October 2016 • Author: Niamh Louise Marriott, Digital Content Producer
TiGenix‘s drug candidate, Cx601, developed for the treatment of complex perianal fistulas in Crohn’s disease patients, has been granted orphan drug designation status in Switzerland, its second designation for the product.
Developed by TiGenix and recently licensed to Takeda Pharmaceutical, for the exclusive development and commercialisation outside the US, Cx601 is a suspension of allogeneic adipose-derived stem cells (eASC) injected intra-lesionally for the treatment of complex perianal fistulas in patients with Crohn’s disease that have had an inadequate response to at least one conventional or biologic treatment.
Crohn’s disease is a chronic inflammatory disease of the gastrointestinal tract. People living with Crohn’s disease can experience complex perianal fistulas for which there are limited treatment options.
Clinical supporting data
In September this year, Takeda received orphan drug status from the Swiss Agency for Therapeutic Products (Swissmedic) regarding the application dossier for Cx601, or eASCs, adipose-derived stem cells for the rare disease anal fistulas. This decision was based on the recognition of the European Commission’s orphan drug designation in 2009, as well as the supporting data provided to the agency, which addressed proof of quality, efficacy and safety, as well as the rarity of the disease.
“The preparation and success of this dossier was a great start to our recently formalised partnership with Takeda and speaks to the important medicinal value of Cx601 in an area of high unmet medical need,” said Maria Pascual, Vice President Regulatory Affairs and Corporate Quality of TiGenix.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics